Genentech announced today that it received FDA approval for its Susvimo injection for treating macular degeneration (AMD). South San Francisco-based Genentech, a member of the Roche Group, designed its Susvimo ranibizumab injection (100 mg/mL) for intravitreal use via ocular implant for treating people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded […]
Featured
Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated […]
Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes
Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes. Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared […]
Medtronic touts data for MiniMed 780G insulin pump in children
Medtronic (NYSE:MDT) reported positive one-year, real-world clinical data for its MiniMed 780G insulin pump platform in children. Data came from a subset of 3,211 pediatric and adolescent patients (15 years old and below) with type 1 diabetes using the MiniMed 780G system with the Guardian Sensor 3 in Europe. According to a news release, the […]
Phillips-Medisize expands its global manufacturing capacity
Phillips-Medisize announced today that it expanded its global manufacturing capacity through several collaborations and internal initiatives. Hudson, Wisconsin-based Phillips-Medisize, a Molex company, said its global reach now encompasses 36 world-class facilities with scalable, end-to-end capabilities tailored to help customers bring products to market quickly and efficiently from anywhere in the world. Get the full story […]
Ultrahuman hires chief business officer as it scales expansion for glucose monitoring tech
Metabolic tracking technology developer Ultrahuman announced today that it appointed Bhuvan Srinivasan as its first chief chief business officer. The appointment of Srinivasan to the new role follows Bangalore, India-based Ultrahuman’s $17.5 million Series B financing round completed in August. Ultrahuman develops the Ultrahuman Cyborg, a continuous metabolism tracker designed to help people with diabetes […]
Insulet announces board of director changes
Insulin delivery technology developer Insulet (NSDQ:PODD) announced today that it appointed Dr. Luciana Borio to its board of directors. Borio joins the board of Acton, Massachusetts–based Insulet, having served in key roles with the FDA, the National Security Council and the Council on Foreign Relations. She specializes in biodefense and medical countermeasures, emerging infectious diseases, […]
Report: Medtronic in negotiations to buy Israel-based insulin pump maker Triple Jump
Reports in Israel say that Medtronic (NYSE:MDT) has entered talks to acquire Triple Jump for $300 million. Calcalist reported that the proposed acquisition, which is in advanced negotiations, follows a 2020 investment into Triple Jump made by Medtronic that included an option to purchase the insulin pump maker. Triple Jump — a startup based in […]
Navidea names two appointments to its board of directors
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it appointed two new members to its board of directors. Thomas Forest Farb-Horch and Agnieszka Winkler joined Dublin, Ohio-based Navidea’s board, effective Oct. 7, each with a three-year term ending concurrently with the company’s 2024 annual stockholders meeting. According to a news release, Farb-Horch, a veteran of over three […]
Corium touts study results for once-daily ADHD capsule
Corium (NSDQ:CORI) today announced clinical data demonstrating the strong performance of its once-daily ADHD capsule. Boston-based Corium’s Azstarys oral capsule for treating ADHD symptoms (serdexmethylphenidate [SDX] and dexmethylphenidate [d-MPH]) received FDA approval in March as the first and only product containing a d-MPH oral prodrug for treating ADHD (attention deficit hyperactivity disorder) symptoms in patients […]
